80,422 Shares in ImmunityBio, Inc. $IBRX Bought by Retirement Planning Group LLC

Retirement Planning Group LLC bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the first quarter, according to its most recent filing with the SEC. The firm bought 80,422 shares of the company’s stock, valued at approximately $617,000.

Several other institutional investors have also recently bought and sold shares of IBRX. AQR Capital Management LLC lifted its position in ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after acquiring an additional 29,297 shares during the last quarter. Creative Planning grew its position in shares of ImmunityBio by 9.2% in the second quarter. Creative Planning now owns 62,028 shares of the company’s stock valued at $164,000 after purchasing an additional 5,231 shares during the last quarter. Cetera Investment Advisers increased its stake in shares of ImmunityBio by 56.9% in the second quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock worth $49,000 after purchasing an additional 6,731 shares during the period. JPMorgan Chase & Co. increased its stake in shares of ImmunityBio by 5.2% in the second quarter. JPMorgan Chase & Co. now owns 1,071,736 shares of the company’s stock worth $2,829,000 after purchasing an additional 52,782 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of ImmunityBio by 11.8% during the 2nd quarter. Legal & General Group Plc now owns 205,478 shares of the company’s stock worth $542,000 after purchasing an additional 21,715 shares during the last quarter. Institutional investors own 8.58% of the company’s stock.

Insider Transactions at ImmunityBio

In other news, Director Cheryl Cohen sold 131,210 shares of ImmunityBio stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the sale, the director owned 125,386 shares of the company’s stock, valued at approximately $1,191,167. This trade represents a 51.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total value of $197,000.00. Following the sale, the director owned 2,802,788 shares in the company, valued at approximately $22,085,969.44. This represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 435,443 shares of company stock valued at $3,918,819. 66.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

IBRX has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research note on Friday, July 10th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a report on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and issued a $12.00 price objective on shares of ImmunityBio in a research report on Thursday, May 21st. Finally, D. Boral Capital restated a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research note on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.20.

ImmunityBio Stock Performance

Shares of IBRX opened at $7.73 on Thursday. The company has a 50-day simple moving average of $7.85 and a 200-day simple moving average of $7.12. ImmunityBio, Inc. has a 52 week low of $1.95 and a 52 week high of $12.43. The firm has a market capitalization of $8.10 billion, a P/E ratio of -9.09 and a beta of 0.01.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The company had revenue of $44.21 million during the quarter, compared to analyst estimates of $43.07 million. As a group, equities analysts forecast that ImmunityBio, Inc. will post -0.31 earnings per share for the current year.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.